Sumitomo Pharmaceuticals Company Limited

Dainippon Sumitomo Pharma Co., Ltd.

Koji Morishita

Naohito Ohashi

Masami Muraoka

Masatoshi Yuri

Kazuki Matsui

Nagisa Aida

Masashi Tanaka

Yoshihide Ueno

Takaaki Yamamoto

Seiji Katayama

An optically active form of the quinazolinone derivatives represented by the general formula (1): [wherein Y represents a phenyl group or C2-C7 alkyl group; E represents &#x2014;CH&#x2550; or nitrogen atom; and R represents a C1-C4 alkyl group and so on], or pharmaceutically acceptable salts thereof, has a selective antagonism for the M3 muscarinic receptor and depressant action on the frequency of rhythmic bladder contractions, and it is useful for the treatment of pollakiuria and urinary incontinence.

Quinazolinone derivative

Quinazolinone derivatives

Pyridone derivatives and process for preparing the same

A process for preparing a pyridone derivative (4), which comprises reacting the compound (1) with a hypochlorite or a hypobromite or with lead tetraacetate to give the compound (2), and reacting the compound (2) with the compound (3). Said process is preferably especially from the standpoint of safety.

Preparation of pyridone derivatives using phthalimido containing starting material

LDL receptor gene expression promoters

Growing community of inventors

Nishinomiya, Japan

Koji Morishita